HYBIO(SZ:300199) Xin Lang Cai Jing·2025-08-26 07:40Company Overview - Hanyu Pharmaceutical Co., Ltd. is located in Longhua District, Shenzhen, Guangdong Province, and was established on April 2, 2003. The company went public on April 7, 2011. Its main business involves chemical pharmaceuticals and medical devices, with 100% of its revenue coming from the pharmaceutical manufacturing sector [1]. Stock Performance - On August 26, Hanyu Pharmaceutical's stock fell by 5.01%, closing at 27.50 CNY per share. The trading volume was 2.956 billion CNY, with a turnover rate of 14.14%, and the total market capitalization reached 24.289 billion CNY [1]. Fund Holdings - According to data from the top ten holdings of funds, one fund under Bosera Asset Management holds a significant position in Hanyu Pharmaceutical. The Bosera CSI Taogold Big Data 100A fund (001242) reduced its holdings by 32,100 shares in the second quarter, now holding 132,100 shares, which accounts for 1.02% of the fund's net value, ranking it as the ninth largest holding. The estimated floating loss today is approximately 191,500 CNY [2]. Fund Performance - The Bosera CSI Taogold Big Data 100A fund was established on May 4, 2015, with a current scale of 148 million CNY. Year-to-date, the fund has achieved a return of 27.05%, ranking 1462 out of 4222 in its category. Over the past year, it has returned 60.56%, ranking 1302 out of 3764, and since inception, it has returned 26.57% [2]. Fund Management - The fund manager of Bosera CSI Taogold Big Data 100A is Yang Zhenjian, who has been in the position for 6 years and 269 days. The total asset scale of the fund is 17.222 billion CNY, with the best return during his tenure being 67.12% and the worst being -0.6% [3].